Illinois Municipal Retirement Fund Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Illinois Municipal Retirement Fund boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 21,837 shares of the biopharmaceutical company's stock after buying an additional 2,774 shares during the quarter. Illinois Municipal Retirement Fund's holdings in Regeneron Pharmaceuticals were worth $13,850,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Capital International Investors raised its holdings in shares of Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after purchasing an additional 155,369 shares during the last quarter. Dodge & Cox grew its position in Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after purchasing an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after buying an additional 810,144 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after buying an additional 149,124 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on REGN shares. The Goldman Sachs Group reduced their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a research note on Monday, June 2nd. Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Finally, Bank of America reduced their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $822.58.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN remained flat at $521.00 during trading hours on Friday. The company's stock had a trading volume of 1,607,735 shares, compared to its average volume of 897,423. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The company has a market capitalization of $56.25 billion, a price-to-earnings ratio of 13.26, a price-to-earnings-growth ratio of 1.91 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The company's 50 day moving average is $555.02 and its 200 day moving average is $634.70.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the prior year, the firm posted $9.55 EPS. Regeneron Pharmaceuticals's revenue was down 3.7% on a year-over-year basis. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.68%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.